Kahrom Hadi, Aghajanzadeh Manouchehr, Asgari Mohammad Reza, Kahrom Mahdi
Department of General Surgery, Guilan University of Medical Sciences, Rasht, Iran.
Department of Cardiovascular Surgery, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Indian J Palliat Care. 2017 Jan-Mar;23(1):53-56. doi: 10.4103/0973-1075.197958.
Malignant pleural effusion (MPE) is determined by the detection of malignant cells in pleural fluid or pleural tissue. Neoplasm of lung, breast, ovary and lymphoma are the causes of more than 75% of MPE. Pleurodesis is a usual technique in the management of MPE to achieve a symphysis between two layers of the pleura, and various chemical agents have been used in an attempt to produce pleurodesis. With regard to complications and limitations of these sclerosing agents, efficacy and safety of povidone-iodine have been investigated in this study.
Between June 2014 and June 2016, 63 consecutive patients were admitted to the Department of Thoracic Surgery because of symptomatic MPE. After insertion of a chest tube, pleurodesis with instillation of povidone-iodine was performed. Thyroid and renal function tests were checked, and success rate as well as recurrence of MPE was monitored in the next follow-up visits.
The complete response to this procedure was about 53.57%, and failure of treatment was 10.71% with efficacy of 82.2%. The most common complication was pain during instillation (26.9%). Changes in thyroid and renal function tests were not significant.
Povidone-iodine is a safe and effective agent with minor side effects in pleurodesis of patients with MPEs and can be used as an accessible and low-cost alternative than other sclerosing agents.
恶性胸腔积液(MPE)通过在胸腔积液或胸膜组织中检测到恶性细胞来确定。肺癌、乳腺癌、卵巢癌和淋巴瘤是超过75%的MPE的病因。胸膜固定术是治疗MPE的常用技术,目的是使两层胸膜粘连,人们尝试使用各种化学药物来实现胸膜固定。鉴于这些硬化剂的并发症和局限性,本研究对聚维酮碘的疗效和安全性进行了调查。
2014年6月至2016年6月,63例因有症状的MPE连续入住胸外科。插入胸管后,进行聚维酮碘滴注胸膜固定术。检查甲状腺和肾功能,在接下来的随访中监测MPE的成功率和复发情况。
该手术的完全缓解率约为53.57%,治疗失败率为10.71%,有效率为82.2%。最常见的并发症是滴注时疼痛(26.9%)。甲状腺和肾功能检查的变化不显著。
聚维酮碘是一种安全有效的药物,在MPE患者的胸膜固定术中副作用较小,与其他硬化剂相比,可作为一种方便且低成本的替代药物。